Lilly scores with new RA med; Bayer trounces FTC's marketing lawsuit; NICE greenlights Zydelig in CLL, rejects Otezla for psoriasis;

> Eli Lilly & Co. ($LLY) and Incyte ($INCY) said their experimental rheumatoid arthritis drug baricitinib beat a standard therapy, methotrexate, at quashing symptoms of the disorder. Report

> Bayer beat back allegations from the Federal Trade Commission, which had sued the drugmaker over marketing claims about a dietary supplement, Phillips' Colon Health. Report

> England's cost-effectiveness watchdogs gave their final blessing to Gilead Sciences' ($GILD) leukemia drug Zydelig, but nixed Celgene's ($CELG) anti-inflammatory drug Otezla for psoriasis. Report | Report

> AstraZeneca's ($AZN) new dose of Brilinta is available in U.S. pharmacies, the company said. Release

> Merck KGaA's consumer health business is looking to Latin America for growth. Release

And Finally... Novartis ($NVS) used fitness wearables in a virtual triathlon challenge for employees. Report

Suggested Articles

Leaked details about an ad campaign to quell coronavirus fears before the election raise "every red flag I could dream of," an ex-HHS official said.

The FDA approved GlaxoSmithKline's Nucala to treat hypereosinophilic syndrome, making it the first biologic approved for that disease.

There’s an emerging trend within the SMA community to pair treatments up in the hope that they may provide even better outcomes, one analyst notes.